Business news, market intelligence, and global industry analysis.
The Latest

Zydus Lifesciences gets FDA final approval for Acyclovir Cream

byPallavi Madhiraju
March 3, 2023
Zydus Lifesciences gets FDA final approval for Acyclovir Cream
Zydus Lifesciences gets FDA final approval for Acyclovir Cream. Photo courtesy of Zydus Cadila.
Total
0
Shares
0
0
0

Zydus Lifesciences (formerly Cadila Healthcare) has secured final approval for Acyclovir Cream, 5% from the US Food and Drug Administration (FDA)

Acyclovir Cream, 5% is a generic of Zovirax Cream.

According to Zydus Lifesciences, Acyclovir belongs to the antivirals class of medications.

Acyclovir cream is indicated for the treatment of cold sores, including fever blisters and blisters resulting from the herpes simplex virus on the lips or face.

Zydus Lifesciences gets FDA final approval for Acyclovir Cream
Zydus Lifesciences gets FDA final approval for Acyclovir Cream. Photo courtesy of Zydus Cadila.

Zydus Lifesciences said that it will launch the product soon in the US market with its manufacturing to take place at its topical manufacturing facility in Changodar, Ahmedabad, India.

As per IQVIA MAT December 2022, the annual sales of Acyclovir Cream, 5% in the US was $16.9 million.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Is Orencia finally vulnerable? Dr. Reddy’s abatacept biosimilar clears a key FDA hurdle
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m

Mallinckrodt sale of BioVectra to H.I.G. Capital : Irish biopharma company Mallinckrodt has agreed to divest its wholly-owned subsidiary BioVectra, a Canadian CDMO (contract development and manufacturing organization) to an affiliate of H.I.G. Capital for nearly US$250 million, as per the latest pharma acquisition news. The transaction amount to be paid by H.I.G. Capital, which is […]

The post Mallinckrodt to sell Canadian CDMO BioVectra to H.I.G. Capital for $250m appeared first on PharmaNewsDaily.com.

bySrinath